Breakthrough in imaging? Lung tumors identified at millimeter size

A preclinical study presents an experimental MRI contrast agent that detects tiny lung tumors and metastases in animal models. The agent binds to collagen in the tumor environment, highlighting it on scans. Researchers hope it may enable early diagnosis without radiation in the future, but its efficacy and safety in humans have not yet been tested.

A preclinical study presents an experimental MRI contrast agent that successfully detected tiny lung tumors and metastases as small as one millimeter in animal models. The agent was developed to bind to type 1 collagen, a structural protein found at high levels in the environment of invasive lung tumors. The researchers focused not only on the cancer cells but on changes in the surrounding tissue, which may help assess the aggressiveness of the disease. The potential advantage is imaging without ionizing radiation, but the research is at a very early stage. Researchers will need to examine safety, dosage, and the ability to distinguish between cancerous tissue and benign conditions, and then proceed to clinical trials and regulatory approval. As of now, this is a promising proof of concept that does not change the way patients are diagnosed or monitored.